BELLUS Health Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (RCC). Camlipixant is a highly selective antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. It is being evaluated in the CALM phase III clinical development programmed. It is developing camlipixant for the treatment of adults with RCC. Camlipixant has the potential to address the significant unmet need for an efficacious, safe and well tolerated treatment for refractory chronic cough.

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed Toronto S.E. Other stock markets 00:00:00 30/06/2023 +04			5-day change	1st Jan Change
19.48 ^CAD	-0.10%		-.--%	-

07-24	BluEnergies Completes C$20.7 Million Private Placement; Haywood Advisory Deal Extended	MT
07-22	BluEnergies Upsizes Private Placement to C$20.7 Million on Strong Demand	MT

Market Cap	1.86B 1.62B 1.51B 1.38B 2.61B 177B 2.64B 17.69B 6.94B 88.73B 7B 6.85B 294B	P/E 2021	-8.95x	P/E 2022	-12.4x
Enterprise Value	1.53B 1.32B 1.23B 1.14B 2.14B 145B 2.17B 14.51B 5.69B 72.75B 5.74B 5.62B 241B	EV / Sales 2021	36,416x	EV / Sales 2022	43,771x
Free-Float	81.52%	Yield 2021 *	-	Yield 2022	-

07-24	BluEnergies Completes C$20.7 Million Private Placement; Haywood Advisory Deal Extended	MT
07-22	BluEnergies Upsizes Private Placement to C$20.7 Million on Strong Demand	MT
07-09	BluEnergies to Raise C$10.13 Million Via Non-Brokered Private Placement of Units	MT
07-06	BluEnergies Says Liberia's Harper Basin Exploration Progressing as Planned	MT
04-27	BluEnergies Announces DTC Eligibility	MT
03-30	BluEnergies Says Its Shares Have Begun Trading on OTCQX Best Market	MT
08/05/25	BluEnergies Names Craig Steinke as Chief Executive	MT
29/06/23	BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Capped Composite Index	CI
29/06/23	BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Completion Index	CI
29/06/23	BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Composite Index	CI
29/06/23	BELLUS Health Inc.(TSX:BLU) dropped from S&P Global BMI Index	CI
28/06/23	GSK completes acquisition of chronic cough-focused Bellus Health	AN
28/06/23	GSK Completes $2 Billion Acquisition of BELLUS Health	MT

19/04/23	RBC Downgrades BELLUS Health to Sector Perform From Outperform, Cuts Price Target to $14.75 From $21 Amid GSK Deal; Speculative Risk Kept	MT
18/04/23	Jefferies Downgrades BELLUS Health to Hold From Buy, Cuts Price Target to $14.75 From $21	MT
18/04/23	BTIG Downgrades BELLUS Health to Neutral From Buy	MT
18/04/23	LifeSci Capital Downgrades BELLUS Health to Market Perform From Outperform, Adjusts Price Target to $14.75 From $24	MT
18/04/23	TD Cowen Downgrades BELLUS Health to Market Perform From Outperform, Adjusts Price Target to $14.75 From $15	MT

BELLUS Health Stock

Stocks

BLU

CA07987C2040

Biotechnology & Medical Research

Valuation: BELLUS Health

Latest news : BELLUS Health

Analysts' recommendations: BELLUS Health

Press Releases: BELLUS Health

News in other languages: BELLUS Health

Quotes and Performance

Course Extremes

Managers and Directors: BELLUS Health

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

30/09/24	Bloom Burton & Co. - Roberto Bellini Receives the 2024 Bloom Burton Award	AQ
02/08/24	Chronic Refractory Cough Pipeline 2024 \| GSK, Trevi Therapeutics	AQ
28/06/23	BELLUS Health : MATERIAL CHANGE REPORT - Form 6-K	PU
28/06/23	GSK completes acquisition of BELLUS Health \| GSK	AQ
28/06/23	Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health	AQ

13/12/23	Pharma und Gesundheit: weitere Konsolidierung
12/12/23	Farma en gezondheid: consolidatie gaat door
11/12/23	Farmaceutica e salute: continua il consolidamento
11/12/23	Farmacia y salud: La consolidación continúa
28/06/23	GSK : l'acquisition de Bellus Health est finalisée

Manager	Title	Age	Since
Jeremy Martin PSD	President	-	01/06/2023
Ramzi Benamar DFI	Director of Finance/CFO	53	07/12/2020
Denis Garceau CTO	Chief Tech/Sci/R&D Officer	69	01/01/2010

Director	Title	Age	Since
Francesco Bellini CHM	Chairman	79	01/01/2002
Pierre Larochelle BRD	Director/Board Member	54	01/06/2009
Joseph Rus BRD	Director/Board Member	80	01/06/2009

Date	Insider	Type	Main position	Quantity	% Market Cap.
29/06/23	GSK PLC	Other	Company	0	0%
22/06/23	Pierre Larochelle	Option	Director	27,777	0.0219%
22/06/23	Tony Matzouranis	Option	Executive/Senior Manager	75,000	0.0593%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BELLUS HEALTH	-0.10%	-.--%	-.--%	-.--%	1.87B
WUXI APPTEC CO., LTD.	+4.35%	+19.90%	+60.59%	+95.21%	62.53B
ARGENX SE	+2.83%	-3.48%	+24.97%	+69.33%	52.43B
BIONTECH SE	-0.28%	-2.02%	-18.01%	-7.54%	23.1B
INSMED INCORPORATED	+1.32%	-2.67%	-10.07%	+358.94%	21.4B
WUXI BIOLOGICS (CAYMAN) INC.	+0.40%	+5.29%	+30.11%	-9.63%	21.17B
GENMAB A/S	+0.75%	+1.34%	+32.22%	-25.54%	17.76B
PHARMAESSENTIA CORPORATION	+9.88%	+19.73%	+229.67%	+385.49%	15.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+2.08%	-3.28%	+21.67%	+564.59%	14.68B
EXELIXIS, INC.	+0.96%	+2.33%	+51.15%	+179.60%	14.08B
Average	+2.26%	+3.32%	+42.23%	+161.04%	24.45B
Weighted average by Cap.	+2.74%	+4.56%	+41.99%	+135.87%

	2021	2022
Net sales	16K 13.86K 12.92K 11.88K 22.43K 1.52M 22.68K 152K 59.58K 761K 60.09K 58.77K 2.52M	16K 13.86K 12.92K 11.88K 22.43K 1.52M 22.68K 152K 59.58K 761K 60.09K 58.77K 2.52M
Net income	-71.22M -61.69M -57.5M -52.89M -99.84M -6.77B -101M -676M -265M -3.39B -268M -262M -11.22B	-76.08M -65.89M -61.42M -56.49M -107M -7.23B -108M -722M -283M -3.62B -286M -279M -11.99B
Net Debt	-248M -215M -200M -184M -348M -23.58B -351M -2.35B -923M -11.8B -931M -911M -39.07B	-336M -291M -271M -249M -471M -31.93B -476M -3.19B -1.25B -15.97B -1.26B -1.23B -52.91B

5 years	3.69		19.9
10 years	0.76		19.9